Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Neurol ; 265(4): 764-773, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29392459

RESUMEN

INTRODUCTION: Improving quality of life (QoL) is a key issue when dealing with Parkinson's disease (PD). Integrative care shows potential to achieve improvements in QoL. Here, we analyzed whether a community-based, open-label, integrated approach improves QoL in PD patients. METHODS: PD patients were screened for eligibility and evaluated by a university-based PD specialist, a PD nurse, and a general neurologist at a local practice. Patients were randomly assigned to a control group (CG), receiving standard German neurological treatment including a baseline assessment and follow-up visit at 6 months, or an interventional group (IG) who received an individually tailored therapy plan and additional home visits. Patients and investigators were not blinded for either intervention. Primary outcome analysis compared the differential change of PDQ-39 from baseline to 6-month follow-up between CG and IG. Between-group changes in mood, motor/non-motor functioning, and cognition were secondary outcomes. RESULTS: 300 patients were included and randomized equally to IG and CG. 132 IG and 125 CG patients had a valid PDQ-39 at follow-up and qualified for the modified ITT analysis. PDQ-39 improved more in IG compared to CG [2.2 points (95% CI - 4.4 to 0.1); p = 0.044]. Likewise, change scores between IG and CG favored IG for UPDRS III (p < 0.001, mean change 3.3, 95% CI - 4.9 to - 1.7) and PD-NMS (p < 0.001, mean change 11.3, 95% CI - 17.1 to - 5.5). CONCLUSIONS: Data show that an integrated approach, compared to regular PD care, improves QoL as well as motor and nonmotor PD symptoms over 6 months. Future studies need to address the cost-benefit ratio and whether positive effects can be maintained beyond intervention.


Asunto(s)
Manejo de la Enfermedad , Enfermedad de Parkinson/psicología , Enfermedad de Parkinson/terapia , Atención Primaria de Salud/métodos , Calidad de Vida/psicología , Anciano , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
2.
Transl Psychiatry ; 2: e94, 2012 Mar 20.
Artículo en Inglés | MEDLINE | ID: mdl-22832859

RESUMEN

Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychotic symptoms. Furthermore, enhanced anandamide signaling let to a lower transition rate from initial prodromal states into frank psychosis as well as postponed transition. In our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsychotic, in acute schizophrenia to evaluate the clinical relevance of our initial findings. Either treatment was safe and led to significant clinical improvement, but cannabidiol displayed a markedly superior side-effect profile. Moreover, cannabidiol treatment was accompanied by a significant increase in serum anandamide levels, which was significantly associated with clinical improvement. The results suggest that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.


Asunto(s)
Antipsicóticos/uso terapéutico , Ácidos Araquidónicos/fisiología , Cannabidiol/uso terapéutico , Endocannabinoides/fisiología , Esquizofrenia/tratamiento farmacológico , Psicología del Esquizofrénico , Transducción de Señal/efectos de los fármacos , Sulpirida/análogos & derivados , Enfermedad Aguda , Adulto , Amidas , Amisulprida , Ácidos Araquidónicos/sangre , Método Doble Ciego , Quimioterapia Combinada , Endocannabinoides/sangre , Etanolaminas/sangre , Femenino , Humanos , Masculino , Ácidos Oléicos/sangre , Ácidos Palmíticos/sangre , Alcamidas Poliinsaturadas/sangre , Escalas de Valoración Psiquiátrica , Esquizofrenia/fisiopatología , Transducción de Señal/fisiología , Sulpirida/uso terapéutico , Adulto Joven
3.
Allergy ; 65(4): 420-34, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20028374

RESUMEN

When initiating grass pollen immunotherapy for seasonal allergic rhinoconjunctivitis, specialist physicians in many European countries must choose between modalities of differing pharmaceutical and regulatory status. We applied an evidence-based medicine (EBM) approach to commercially available subcutaneous and sublingual Gramineae grass pollen immunotherapies (SCIT and SLIT) by evaluating study design, populations, pollen seasons, treatment doses and durations, efficacy, quality of life, safety and compliance. After searching MEDLINE, Embase and the Cochrane Library up until January 2009, we identified 33 randomized, double-blind, placebo-controlled trials (including seven paediatric trials) with a total of 440 specific immunotherapy (SIT)-treated subjects in seven trials (0 paediatric) for SCIT with natural pollen extracts, 168 in three trials (0 paediatric) for SCIT with allergoids, 906 in 16 trials (five paediatric) for natural extract SLIT drops, 41 in two trials (one paediatric) for allergoid SLIT tablets and 1605 in five trials (two paediatric) for natural extract SLIT tablets. Trial design and quality varied significantly within and between SIT modalities. The multinational, rigorous trials of natural extract SLIT tablets correspond to a high level of evidence in adult and paediatric populations. The limited amount of published data on allergoids prevented us from judging the level of evidence for this modality.


Asunto(s)
Desensibilización Inmunológica/métodos , Medicina Basada en la Evidencia , Ensayos Clínicos Controlados Aleatorios como Asunto , Rinitis Alérgica Estacional/prevención & control , Administración Sublingual , Método Doble Ciego , Humanos , Inmunoterapia/métodos , Inyecciones Subcutáneas , Extractos Vegetales/administración & dosificación , Extractos Vegetales/inmunología , Poaceae/inmunología
4.
AJR Am J Roentgenol ; 177(6): 1397-403, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11717093

RESUMEN

OBJECTIVE: The purpose of our study was to compare the diagnostic performance of a digital selenium detector (Thoravision) with that of analog film-screen systems and digital luminescence radiography in skeletal radiography for the detection of fissures and lesions in porcine bones. MATERIALS AND METHODS: One hundred bones taken from domestic pigs (50 ribs and 50 femurs) were divided into two equal groups. Fissures and bone lesions were created in 50 bones and 50 served as controls. The bones were examined using film-screen systems, digital luminescence radiography, and digital selenium radiography at various doses. Digital selenium radiography exposure values were adapted to the image geometry differing from the reference methods with a detector focus distance of 2.15 m. Four radiologists independently evaluated image quality and detectability of fissures and lesions on a five-point scale of confidence. Statistical evaluation was based on receiver operating characteristic curve analysis. RESULTS: Fissures and bone lesions were detected most reliably using the mammography film-screen system, but the difference in the results of the analog and digital reference images did not achieve statistical significance. CONCLUSION: Compared with analog film-screen systems, the lower spatial resolution of the digital selenium and digital luminescence radiography systems does not affect detectability of fissures and bone lesions in porcine bone. Selenium is effective in skeletal radiography for detecting fissures and bone lesions. With digital selenium and digital luminescence radiography, the surface dose can be cut to half that required for 200-speed film-screen systems without losing any diagnostically relevant information.


Asunto(s)
Enfermedades Óseas/diagnóstico por imagen , Luminiscencia , Intensificación de Imagen Radiográfica , Selenio , Pantallas Intensificadoras de Rayos X , Animales , Porcinos
5.
Endocrinology ; 141(11): 4136-45, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11089546

RESUMEN

The up-regulation of oxytocin (OT) receptors in rabbit amnion at the end of gestation is associated with a large increase in the ability of OT to stimulate PGE2 synthesis. The purpose of these investigations was to determine what other factors contribute to this increase. OT enhanced PGE2 synthesis at several levels. The concentrations of cytosolic phospholipase A2, which generates arachidonic acid for PGE2 synthesis, and PGH endoperoxide synthases (types 1 and 2), which catalyze the conversion of arachidonic acid to prostanoids, rose substantially in rabbit amnion at term. OT stimulated translocation of cytosolic phospholipase A2 to the cell particulate fraction, presumably by a Ca2+-mediated process, and phosphorylation of cytosolic phospholipase A2 via the extracellular regulated protein kinase 2/1-mediated pathway. OT-stimulated increases in intracellular Ca2+ concentrations and extracellular regulated protein kinase 2/1 phosphorylation were both mediated by G(q/11) activation. OT also increased the expression of PGH endoperoxide synthase-2 after treatment of amnion cells in culture for 2 h; however, PGE2 release in response to OT was virtually immediate. These findings show that the rapid stimulation of PGE2 synthesis by OT occurs through cytosolic phospholipase A2 activation and PGH endoperoxide synthase-1 activity, both of which, along with OT receptor concentrations, are considerably up-regulated in the amnion at the end of gestation.


Asunto(s)
Amnios/efectos de los fármacos , Amnios/metabolismo , Dinoprostona/biosíntesis , Edad Gestacional , Oxitocina/farmacología , Amnios/enzimología , Animales , Ácido Araquidónico/metabolismo , Calcio/metabolismo , Citosol/enzimología , Femenino , Isoenzimas/genética , Isoenzimas/metabolismo , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Fosfolipasas A/análisis , Fosfolipasas A/genética , Fosfolipasas A/metabolismo , Fosfolipasas A2 , Fosforilación , Embarazo , Prostaglandina-Endoperóxido Sintasas/análisis , Prostaglandina-Endoperóxido Sintasas/genética , Prostaglandina-Endoperóxido Sintasas/metabolismo , ARN Mensajero/análisis , Conejos , Receptores de Oxitocina/efectos de los fármacos , Receptores de Oxitocina/fisiología
6.
Gastroenterology ; 115(6): 1454-63, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9834273

RESUMEN

BACKGROUND & AIMS: The cyclooxygenase (COX) enzymes catalyze the initial step of prostaglandin formation; the inducible form, COX-2, plays a role in inflammation. Heat-shock protein 70 (hsp70) is a stress-responsive gene important for cell survival; induction of hsp70 appears to be mediated, in part, by the prostaglandin pathway. We determined the effect of COX-2 overexpression on hsp70 induction in rat intestinal epithelial (RIE) cells. METHODS: RIE cells transfected with COX-2 complementary DNA oriented in the sense (RIE-S) or antisense (RIE-AS) direction were subjected to a heat shock; RNA and protein were harvested and analyzed by Northern and Western blots, respectively. Gel shift assays were performed to assess DNA binding. RESULTS: Both hsp70 messenger RNA and HSP70 protein levels were increased in the RIE-AS cells, whereas induction was markedly inhibited in the RIE-S cells after heat shock. Inhibition of heat-shock factor binding was noted in RIE-S cells, suggesting that heat-shock transcription factor regulation may explain the inhibition of hsp70. The COX-2 selective inhibitor, NS-398, reversed the effects of COX-2 overexpression. CONCLUSIONS: The results support a functional role for the prostaglandin/COX pathway in the induction of hsp70. The findings underscore a potential regulatory mechanism involving an inverse relationship between COX-2 expression and hsp70 induction.


Asunto(s)
Proteínas HSP70 de Choque Térmico/fisiología , Isoenzimas/biosíntesis , Peroxidasas/biosíntesis , Prostaglandina-Endoperóxido Sintasas/biosíntesis , Animales , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa/farmacología , Regulación de la Expresión Génica , Nitrobencenos/farmacología , Ratas , Sulfonamidas/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA